Showing 1 - 4 of 4 Skin and Connective Tissue Diseases

Status: Open Not Enrolling

Investigator: Anaum Maqsood

Study Coordinator: Mariana Sandoval

Phone: 713.441.1326

To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab. ... Read more >

Status: Open Not Enrolling

Investigator: Nestor Esnaola

Study Coordinator: Safiya Joseph

Phone: 203.308.8567

The purpose of this research study is to see whether using atezolizumab before surgery is safe and does not cause side effects that delay surgery in participants with cutaneous melanoma that has not spread to other areas of the body (non-metasta ... Read more >

Status: Enrolling

Investigator: Monisha Singh

Study Coordinator: Safiya Joseph

Phone: 203.308.8567

To evaluate the efficacy and safety of tebentafusp-based regimens tebentafusp monotherapy and in combination with anti-PD1) vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care ( ... Read more >

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Derek Cole

Phone: 713.441.5607

The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), ... Read more >